CDNA vs TMO
CDNA: CareDx is the leading provider of genomics-based molecular diagnostics for transplant patients, combining non-invasive cell-free DNA and gene expression testing with digital health and patient solutions to improve transplant outcomes across heart, kidney, and lung. TMO: Thermo Fisher Scientific is a leading global provider of mission-critical laboratory equipment, analytical instrumentation, and scientific services for research and clinical markets.
Side-by-side fundamentals
| Metric | CDNA | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $37.78 | $526.46 | |
| Market cap as of 2026-07-23 | $2.0B | $194.1B | |
| P/E as of 2026-07-23 | n/a | 28.36 | |
| PEG as of 2026-07-23 | n/a | 2.89 | |
| Net margin as of 2026-07-23 | -2.0% | +15.2% | TMO higher |
| Gross margin as of 2026-07-23 | +68.9% | +40.9% | CDNA higher |
| Operating margin as of 2026-07-23 | -3.9% | +17.5% | TMO higher |
| ROE as of 2026-07-23 | -2.6% | +13.2% | TMO higher |
| ROA as of 2026-07-23 | -1.9% | +6.4% | TMO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.83 | CDNA lower |
| Revenue growth (YoY) as of 2026-07-23 | +19.2% | +5.4% | CDNA higher |
| Revenue CAGR (3y) SEC XBRL | +5.7% | -0.3% | CDNA higher |
| Dividend yield as of 2026-07-23 | n/a | +0.4% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 2.46 | 0.86 | |
| 1-year return as of 2026-07-22 close | +190.2% | +23.1% | CDNA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.